All associations were attenuated and the association with hip fracture was null when incident AF was defined by a primary diagnosis code.
Conclusions. AF was strongly associated with increased risks of ischemic stroke, MI and death, with risks highest soon after AF diagnosis but extending beyond 90 days.
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I N T R O D U C T I O N
Atrial fibrillation/flutter (AF) in patients with end-stage renal disease (ESRD) is common and its prevalence increases steeply with old age in patients on hemodialysis (HD) [1] . Among patients aged 67 years or older who initiated dialysis in the USA in 2007, 33% had AF diagnosed prior to ESRD and an additional 14.5% developed incident AF during the first year of dialysis treatment [2] . Similar to the general population, AF has been associated with higher rates of ischemic stroke [3, 4] , myocardial infarction (MI), heart failure and mortality in patients on dialysis [5, 6] . While in the general population strong evidence supports the efficacy and net benefit of oral anticoagulation in patients with AF who are at increased risk of ischemic stroke, similar evidence remains elusive in patients with advanced chronic kidney disease (CKD), in particular those with ESRD on dialysis [7] . One piece of information that could potentially inform a solution to this clinical conundrum is whether the risks of adverse health events following newly diagnosed AF change over time. If it were the case, for example, that outcomes were highest following newly diagnosed AF, such knowledge about the highest at-risk period might guide indication, timing and duration of anticoagulation treatment following an index episode of AF [8, 9] . This information is currently lacking and motivated the present study in a large cohort of older patients with ESRD on HD. Our objective was to identify the relative rates of acute cardiovascular health events after incident AF, versus otherwise similar patients without AF, with particular focus on the time-dependency of these associations. We specifically hypothesized that the excess rates of acute cardiovascular health events were highest immediately following the index AF episode and decreased thereafter.
M A T E R I A L S A N D M E T H O D S

Study population
We used the US Renal Data System (USRDS) to identify patients newly initiated on HD between January 2006 and December 2011, who had 2 years of uninterrupted Medicare A&B (MPAB) coverage prior to start of dialysis. Since Medicare is the public insurance program for older Americans (age 65 years or older), patients were eligible for selection if they were !67 years on the first treatment date for ESRD. We excluded patients with any evidence of prior AF from pre-ESRD inpatient or outpatient diagnosis codes [International Classification of Diseases, Ninth Revision (ICD-9) Codes: 427.3Â] [10] . Since we aimed to study the outcomes of incident stroke, MI and hip fracture, patients with any of the corresponding diagnoses during the 2-year baseline period were also excluded. Hip fracture was selected as a potential negative control outcome as we expected AF not to be (strongly) associated with this outcome. We also excluded patients with no recorded Medicare Parts A or B claims in the 2 years pre-ESRD (nonusers of the system) as well as any patients 100 years of age or older.
Patient characteristics
We identified patients' demographics [age, sex, race (white, black, Asian, Native American/Pacific Islander), Hispanic ethnicity] from the USRDS Patients file. We used diagnoses from inpatient and outpatient claims submitted to the Centers for Medicare and Medicaid Services to ascertain patients' comorbid conditions. A list of conditions and their respective ICD-9 codes used for ascertainment are shown in Supplementary data, Table S1 .
Exposure
By design, all patients started follow-up free from any prior AF diagnosis. We identified the date of incident AF from inpatient diagnoses (>85% of incident AF in patients on HD is diagnosed in inpatient claims) [11] ; primary analyses considered events in which the exposure (AF) was reflected in primary or any secondary diagnosis fields; sensitivity analyses restricted these index diagnoses to appear in primary diagnosis code positions only.
Time from incident AF was modeled in a time-dependent fashion. We created time-varying dummy variables indicating time since the index AF diagnosis: 30 days, 31 to 90 days and >90 days. These categories were chosen a priori.
Outcomes
We identified the events of mortality (all-cause), ischemic stroke, MI and hip fracture using ICD-9 codes from inpatient claims (Supplementary data, Table S1 ). Ascertaining these outcomes from claims-based algorithms fared well in validation studies, with high specificities and positive predicted values reported [12] [13] [14] [15] [16] . In addition, we identified reported causes of death from the CMS Death Notification (Form CMS-2746). Individual causes were grouped into plausible categories to
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Statistical analysis
Baseline characteristics were tabulated as counts and proportions or means and standard deviations (or medians and interquartile range, for variables not normally distributed) and group comparisons were conducted using chi-squared or t-tests. Person time was counted from the first date of ESRD. Patients were censored at kidney transplantation, first discontinuation of MPAB coverage, at a first outpatient AF diagnosis or end of follow-up or database (31 December 2011). Incidence rates were determined for the events of mortality (all-cause), ischemic stroke, MI and hip fracture and Cox proportional hazard regression models were used to estimate hazard ratios (HR) and their corresponding 95% confidence intervals (CIs). We present results obtained from unadjusted models, from models adjusted for demographics as well as from models adjusted for both demographics and all baseline comorbidities listed in Table 1 . Causes of death were tabulated as percentages of all deaths with reported cause by AF status: no AF, 30 days, 31-90 days or >90 days from first AF.
Analyses were conducted using R software (version 3.3; www.R-project.org). This study was approved by Institutional Review Boards at Stanford University School of Medicine (protocol #17904) and Baylor College of Medicine (protocol #H-36408).
R E S U L T S
We identified 85 377 older patients who initiated HD and had no recorded history of AF, stroke, MI or hip fracture. A cohort selection diagram is shown in Figure 1 . The mean age was 76.5 years and 52.7% were women, 25.4% were non-white and 8.5% were Hispanic. Patients were followed for a mean of 1.8 years (median: 1.5; interquartile range: 0.5-2.8) and contributed a total of 157 149 person-years. Overall, 12 193 (14.3%) of patients were subsequently diagnosed with incident AF; 1813 (14.9%) of those cases had AF coded as the primary diagnosis. Observation time without an AF diagnosis amounted to 146 776 person-years, for an AF incidence of 83.1/1000 personyears; the remaining 10 373 person-years of follow-up occurred after an index AF diagnosis. Patients who developed AF were older, more likely to be white and less likely to be black or Hispanic (Table 1) . Certain comorbidities were also more common in patients who later developed AF, including heart failure, valvular heart disease and pulmonary hypertension.
The overall incidence rates were 35.5 per 1000 person-years for ischemic stroke, 82.9 per 1000 person-years for MI and 26.2 per 1000 person-years for hip fracture; mortality was 270 per 1000 person-years ( Table 2 ). The results from the Cox regression models of AF exposure on outcomes are shown in Table 3 . Generally, model adjustment attenuated all estimates of association somewhat, but not strongly. Hence, we focused on fully adjusted results in this narrative; detailed unadjusted and demographics-adjusted results are reported in Table 3 . Incident AF was associated with an increased adjusted risk of ischemic stroke 1.5-to 2.5-fold, depending on time since the index AF diagnosis: the HR (95% CI) for the exposure of time-varying AF (versus no AF) was 2. 1.2 (1.1-1.4) ].
Associations Table S2 ). Incident AF when noted as primary diagnosis was not associated with hip fracture during any time window of follow-up.
D I S C U S S I O N
AF is common in patients with ESRD requiring dialysis. A recent study from Taiwan of adults (mean age 61.7 years) with ESRD showed an incidence rate of 12.1 per 1000, which was 1.7 times higher than in patients with less advanced CKD (7.3 per 1000) and 2.4-fold (5.0 per 1000) higher than in the general population without diagnosed kidney disease [17] . Age is a strong risk factor for AF; Goldstein et al. [2] reported an AF incidence rate as high as 148 per 1000 person-years during the first year of HD, in a cohort of 258 605 US Medicare-insured patients 67 years and older who initiated HD between 1995 and 2007. Our study used a similar, albeit more contemporary cohort with selection criteria leading to a relatively healthier cohort of older patients (no MI, Outcomes after incident atrial fibrillation in HD stroke or hip fracture in 2 years pre-ESRD) and showed an AF incidence of 83.1 per 1000 person-years.
In the current study, we found that AF increased the risks of ischemic stroke, MI and death considerably, and in a time-dependent manner, with risks being highest in the months immediately following the AF diagnosis and then tapering off (but remaining elevated) in the longer term. One notable aspect of our study is that we considered incident, and time since first diagnosis of, AF as a time-varying covariate in the ESRD population. This unique feature of our study may provide crucial new information and inform considerations about the optimal timing and duration of anticoagulation for AF in patients with ESRD. It also serves as a reminder that ESRD patients with AF are at exceedingly high risk for not only stroke, but also several other adverse outcomes, especially in the first few months following detection of AF.
We found a significantly increased mortality risk in ESRD patients after incident AF, with an almost 10-fold increase in the first 30 days and an almost 5-fold adjusted increase from 31 to 90 days from initial diagnosis. Beyond 90 days, the mortality risk remained double compared with patients without AF. The magnitude of these risk estimates was quite sensitive to the requirement that incident AF be diagnosed as the primary diagnosis. However, while attenuated, the respective mortality HRs remained rather large after incident AF that was coded as primary diagnosis (5-fold for first 30 days, 3.5-fold for 31-90 days and 1.75-fold beyond 90 days). It is certainly possible that other health events or complications may have precipitated AF and, in turn, contributed to the high early mortality. However, the fact that the associations remained strong when requiring AF to be listed as primary diagnosis indicates that AF and its downstream consequences in and of themselves are likely important contributors to the excessively high rates of adverse health outcomes. An analysis using the Framingham Heart Study cohort showed that AF was associated with an increased risk of death in men [odds ratio (OR)¼1.5; 95% CI 1.2-1.8] and women (OR ¼ 1.9; 95% CI 1.5-2.2) over 10 years of follow-up [18] . Recently, Conen et al. [19] analyzed the Women's Health Study cohort, comprised of women aged 45 years and older, and found an HR for all-cause mortality after incident AF of 2.1 (95% CI 1.6-2.8) over a median time period of 15.4 years. A study of patients with moderate to advanced CKD enrolled in a Californian Health Maintenance Organization found that incident AF (using a time-varying exposure variable) was associated with 66% higher adjusted mortality compared with patients without AF [20] . None of these studies examined the time-dependency of mortality risk among patients with AF.
Cerebrovascular and cardiovascular risks are high in patients with kidney disease, especially among those with ESRD undergoing dialysis. Seliger et al. [21] showed that-depending on sex and race-patients with ESRD had 4-10 times higher rates of ischemic stroke compared with age-matched controls without ESRD. The incidence rate of ischemic stroke in our cohort of older ESRD patients was 35.5 per 1000 person-years, and its risk was more than double in the 3 months after newly diagnosed AF. Even beyond 3 months, the stroke risk remained 50% higher in patients with AF compared with patients without it. Our findings differ quantitatively from a recent study of dually eligible (Medicaid and Medicare) US patients with ESRD initiating dialysis in which AF was also treated as a time-varying covariate [4] . While associated with incident ischemic stroke in these relatively younger patients (mean age 60.6 years), the adjusted HR for AF was 1.3 (95% CI 1.1-1.5), much smaller than in our study where mean age was 76.5 years. Similar results were found in a recent study of ESRD patients from Taiwan, where the propensity score matched HR for ischemic stroke was 1.3 (95% CI 1.1-1.4) [5] . However, neither of these studies considered whether this HR might vary by time since incident AF.
The risk of MI is similarly elevated in ESRD: the incidence of MI in our study was 82.9 per 1000 person-years, and the hazard of MI increased by 69% (Days 1-30) and 117% (Days 31-90) after incident AF; after >90 days from AF, the risk remained elevated, but to a much lesser extent (25%). Our results are similar to studies conducted in non-ESRD populations. For example, in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study [22] , AF was associated with 70% increased risk of incident MI (HR ¼ 1.70; 95% CI 1.26-2.30) in models adjusted for standard risk factors. In individuals with AF, the age-adjusted incidence rate of MI per 1000 person-years was 12.0 (95% CI 9.6-14.9) in those with AF compared with 6.0 (95% CI 5.6-6.6) in those without AF. A recent meta-analysis by Guo et al. [23] included 12 studies and over 169 036 patients and found that AF was associated with a 47% increase in risk of MI (HR ¼ 1.47; 95% CI 1.21-1.80) and in patients free of coronary heart disease at baseline, the risk was increased by 71% (HR ¼ 1.71; 95% CI 1.36-2.14). While our study did not generally exclude patients with preexisting coronary heart disease, we did exclude patients who had a MI in the 2 years prior to ESRD. We used incident hip fracture as a potentially negative control outcome, having expected that AF would not increase the risk of this endpoint. However, we found a small but significant increase in hip fracture risk in patients with AF, with an independent 22% increase in the hip fracture hazard beyond 90 days from AF. It is possible that this association is perhaps caused by arrhythmia-related fall risk, or it may represent residual confounding. In analyses requiring incident AF to be listed as the principal diagnosis, however, this association was not present. In aggregate, these findings suggest that AF is not merely a frailty indicator, but may partially lie on the causal pathway to subsequent adverse cardiovascular outcomes.
What are the implications of our detailed examination of cerebrovascular, cardiovascular and mortality risk as a function of AF incidence and the specific time since first diagnosed? First, these findings highlight that AF is associated with considerable increases in the risks for several adverse outcomes for which patients with ESRD are already at high risk in the absence of AF. The time profile of these risks indicates the need for increased vigilance and particularly attentive dialysis care and risk management in patients newly diagnosed with AF. Second, our findings may inform medical decision-making regarding the use of oral anticoagulation in these patients. Several studies have highlighted the low use of oral anticoagulation in ESRD patients on dialysis. A study that used an USRDS cohort that partially overlaps with our study cohort (but restricted to patients with Medicare Part D prescription coverage) found that only 15% of patients with newly diagnosed AF were initiated on warfarin within 30 days and only $10% more were initiated over 1 year [11] . This therapeutic nihilism may be justified by the lack of benefit, in terms of prevention of ischemic strokes, and apparent harm from oral anticoagulation in several observational studies [11, 24] .
For evaluating risk of ischemic stroke following AF, scoring systems, such as CHADS 2 and CHA 2 DS 2 -VASc, have been designed and they are counterbalanced with bleeding risk scores such as HAS-BLED to determine the risk of bleeding following anticoagulation. While these scoring systems have helped to evaluate the risk of stroke in general population, they have been of limited use in the dialysis population where the vast majority of patients exceeds commonly accepted threshold for both high thromboembolic and bleeding risk. Our findings may offer a potential opening for a more limited approach, specifically focusing on anticoagulation during the initial phase of high excess risk for ischemic stroke. It does appear intriguing to consider short-term anticoagulation for 3 months, when the stroke risk is highest, and then re-evaluate for potential continuation of therapy. Such an approach could be more acceptable to patients and physicians alike and more easily tested in shorter term clinical trials. Indeed, targeted anticoagulation guided by continuous rhythm monitors was recently tested in a pilot study of 59 non-ESRD patients with paroxysmal AF and low stroke risk, with patients anticoagulated for 30 days only after an AF episode exceeding 1 h duration [9, 25] . While such a targeted strategy requires further validation, particularly in patients with ESRD, these types of creative approaches toward risk management in ESRD patients with AF could be considered as an alternative between the extremes of either indefinite anticoagulation or non-initiation of anticoagulation.
Our study has several limitations that should be considered. First, it is based on insurance claims, whose primary purpose is billing, and which may be prone to under-ascertainment, misclassification and other information biases [26] . However, the exposure and all outcomes of interest have been validated against medical records and found to possess high specificity and positive predictive values. Second, we did not consider the potential impact of anticoagulation on the outcomes of interest. To do so, we would need to restrict the cohort substantially to patients with long-term and uninterrupted prescription drug coverage through Medicare Part D. Not doing so is justifiable in light of our recent findings in a similar cohort that initiation of oral anticoagulation was uncommon after incident AF (in <15% of patients), discontinued soon in the majority of patients initiating it and not associated with ischemic stroke, MI or mortality [11] . Similar results have been obtained through other studies including meta-analysis as well [6] . Hence, omission of oral anticoagulant use in our study is unlikely to induce any major bias. Third, we limited ascertainment of AF to the inpatient setting. A previous study has demonstrated that >85% of new AF cases get first diagnosed as inpatients [11] . Fourth, we had very limited biometric data (serum albumin, creatinine, hemoglobin and body mass index) at baseline and no biometric data at all during follow up that would have permitted further adjustment and provided insights into possible mechanisms underlying AF incidence and the associations with the outcomes studied. Our study database did not permit reliable distinction among types of MI or differentiation between ischemic and hemorrhagic stroke as cause of death. Finally, our study was conducted in older individuals initiating HD treatment for ESRD and its generalizability to younger patients or to other countries is uncertain.
In conclusion, the risks of stroke and other important outcomes were independently increased after newly diagnosed AF in older patients undergoing dialysis. These excess risks were found to be most pronounced in the 3 months after incident AF and to taper down to a lower, sustained risk thereafter. Our findings highlight the particular vulnerability for untoward outcomes of older ESRD patients following AF diagnosis. These results may inform future strategies regarding oral anticoagulation in these patients.
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